about
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnessesBromperidol decanoate (depot) for schizophreniaBromperidol decanoate (depot) for schizophreniaAntipsychotic medication for early episode schizophreniaAntipsychotic medication for early episode schizophreniaGenomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.Cognitive-behavioural therapy for psychosis: a status report.Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.Reducing the dose of depot neuroleptics in stable schizophreniaThe appropriateness of routine medication treatment for schizophrenia.Antipsychotic dosing: how much but also how often?Use of conventional antipsychotics and the cost of treating schizophrenia.Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients.Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study.Metabolomic mapping of atypical antipsychotic effects in schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.Comparative effectiveness of antipsychotic drugs in schizophreniaTreatment of the special patient with schizophrenia.Structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review.Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.State of the science on psychosocial interventions for ethnic minoritiesGenome-wide association study of antipsychotic-induced QTc interval prolongation.The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.The Illness Management and Recovery program: rationale, development, and preliminary findings.Multimodal cognitive therapy: combining treatments that bypass cognitive deficits and deal with reasoning and appraisal biases.Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review.Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.Training patients with schizophrenia with the community re-entry module: a controlled study.Recovery from schizophrenia: a four-year study of an inner city cohort.Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study.Concept and Management of Treatment Resistant Schizophrenia (TRS)The Finnish National Schizophrenia Project 1981-1987: 10-year evaluation of its results.Maintenance treatment of schizophrenia: a review of dose reduction and family treatment strategies.Review: treatment of schizophrenia. State of the art.The history of the psychopharmacology of schizophrenia.Schizophrenia and antipsychotic somatic treatment.
P2860
Q24200306-3A5EC376-8821-407F-AEF1-DECAB22D75BDQ24202780-26297551-FA12-4B0E-9A2B-6FF14A67ED4AQ24234287-9059DF33-09D9-4382-AFF9-CA1076852CB9Q24236683-231830E5-5A38-4070-8693-11AB04E7E545Q24243660-70008706-6223-42F9-A016-0D6FD8AE26F2Q24630309-59486F8A-65DB-4ECC-A7C8-8FC9CBB27E32Q33223628-2561B6F4-5106-4F7F-B145-EB6F574DBA03Q33350202-E9FB1C26-206C-4625-8E80-574FD66ECBDBQ33584343-4CE88984-012E-4AC0-8ED5-3F7FDF0ADAE2Q33606084-1CCCCA40-70F1-43A7-983D-BD51006FBDBAQ33726559-9B36653B-5A92-47AC-ACA8-03BE63E0C27AQ33921404-26CCD847-D7A9-4562-81EA-44DE8E0CC863Q33950877-0AC7BB35-2132-457A-BED8-EC1A8C8DC1E0Q34023214-46A983F1-34C3-47E0-B784-7EDAF32D0B0AQ34327345-492B4B16-26A7-428E-A37B-4E89981394BCQ34373482-5D6FB917-4D22-496E-B4A1-B1DBB68397E6Q34571739-4DA0BE82-EBB0-49E3-A214-6AE5DE353D09Q34620002-F22D6C20-3547-4DAC-AB07-EBC0AD37FA04Q34640811-99074A4F-F461-464F-A6BB-1828516F06A2Q35073834-8DF8918F-2808-4B86-A460-C37AC593439BQ35236300-A298084E-647D-482C-B221-82189D439721Q35236370-3B3CD5A4-9A2D-446F-A94E-583CD66749E0Q35586017-4CF1B5BC-2371-4DA5-9437-06068FEE8DB0Q35696059-BEB89881-72CA-4B3B-9909-9BDD92010B5AQ35751627-FB90467F-B159-4D47-A5EF-7F46A94E76CFQ36073692-921A69A2-6F10-49EC-88BE-63203DBEDC1EQ36442322-1FD58F62-F741-4317-990A-1511930C44F8Q36561382-A3024D14-1002-4101-B6D7-E8F195260B29Q37310217-1C5B97E4-8C7B-4DCF-A561-5C6B8ADA3618Q37996445-D1384A48-857F-44F5-A522-8592320B0245Q38632506-FB7CC092-7632-4931-BDF7-5BFE9A64C091Q39749708-337B2558-79EE-40DC-A2F3-B582863B2F05Q39972149-FE64BBD4-EB8D-4A9F-BB28-4D66ACC4E16BQ39995056-E6822DEE-7B09-4687-8B49-C826EB3D2682Q40521264-961D5CD8-F03B-4563-B346-69B3B55559D9Q40866562-EB39EE01-50C4-4EFB-A502-13ADEF2FAD57Q40960279-B554C319-A68D-43F7-AB78-EF43DDEAA610Q41156710-FCACA06F-540A-4D5C-96DA-21F2C2C4C02BQ41380354-2C304D47-A33A-46CB-898D-5D22232787B2Q41459295-154E97A8-333F-4249-B65B-B8C05CD75E98
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Psychopharmacologic treatment of schizophrenia.
@en
type
label
Psychopharmacologic treatment of schizophrenia.
@en
prefLabel
Psychopharmacologic treatment of schizophrenia.
@en
P356
P1476
Psychopharmacologic treatment of schizophrenia.
@en
P2093
P304
P356
10.1093/SCHBUL/19.2.287
P407
P577
1993-01-01T00:00:00Z